Physician profile
Florence I Hsu
NPI 1205894607
$84,084.39
in general payments reported to CMS, 2019-2025
12 companies · $19K in 2025
The $19K reported for 2025 was more than what 93% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $13K · 2021: $11K · 2022: $12K · 2023: $4,997 · 2024: $13K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Consulting Fee: $12K · Travel and Lodging: $1,113 · Food and Beverage: $303 · Education: $37.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,531.71 |
| Consulting Fee | $12,392.72 |
| Travel and Lodging | $1,112.98 |
| Food and Beverage | $303.14 |
| Education | $37.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $35,512.82 | 2019-2025 | Andembry |
| Pharming Healthcare, INC. | $26,400.42 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $8,462.50 | 2020-2025 | |
| Biocryst Pharmaceuticals, INC. | $6,049.14 | 2019-2025 | Orladeyo |
| Amgen INC. | $3,938.72 | 2022 | |
| Biocryst US Sales Co., LLC | $1,375.00 | 2021 | |
| Blueprint Medicines Corporation | $1,260.00 | 2020 | |
| Shire North American Group INC | $900.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $89.68 | 2019 | |
| Genentech USA, INC. | $60.62 | 2019 | |
| Alk-Abello, INC | $35.49 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florence Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.